Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Artrya Limited is an Australian healthcare technology company specializing in advanced imaging solutions for cardiovascular diseases. Its proprietary software, Artrya Salix, utilizes artificial intelligence to analyze cardiac CT scans, offering significant improvements in diagnostic accuracy and efficiency, particularly in the Australian and U.S. markets.
Artrya generates revenue primarily through software licensing and subscription fees for its AI-driven imaging solutions. The company benefits from a first-mover advantage in the AI cardiac imaging space, with a focus on improving diagnostic workflows and patient outcomes, which enhances its pricing power.
Regulatory approvals for new software features or expansions into new markets
Partnerships with healthcare providers and imaging centers
Clinical trial results demonstrating improved diagnostic outcomes
Adoption rates of Artrya Salix in target markets
Technological disruption from competitors developing superior imaging technologies
Regulatory changes impacting the approval process for medical software
Emergence of new entrants in the AI imaging space
Established imaging companies developing in-house AI solutions
Low revenue generation leading to cash flow constraints
Potential future capital requirements for scaling operations
moderate - As a healthcare technology provider, Artrya's business may be somewhat insulated from economic downturns, but overall spending on healthcare technology can be influenced by GDP growth and healthcare budgets.
Interest rates can affect the company's cost of capital and investment in R&D. Higher rates may limit access to financing for expansion and innovation.
minimal - The company has a low debt-to-equity ratio, indicating limited reliance on external financing.
growth - Investors looking for high-growth potential in the healthcare technology sector.
high - The stock has shown significant volatility, evidenced by a 523% return over the past year.
